6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Author(s) Pre or Post Print Version
Author(s) Pre or Post Print Version
Author(s) Pre or Post-Print Version Only
Author(s) Pre Print and Post Print Only
Author(s) Pre Print Only
Author(s) Pre or Post Print Version Only
Author(s) Pre or Post Print Copy